Cargando…
Nobiletin as a Neuroprotectant against NMDA Receptors: An In Silico Approach
Excitotoxicity is a type of neurodegenerative disorder. It caused by excessive glutamate receptor activation, which leads to neuronal malfunction and fatality. The N-methyl-D-aspartate (NMDA) receptors are found in glutamatergic neurons, and their excessive activation is primarily responsible for ex...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229780/ https://www.ncbi.nlm.nih.gov/pubmed/35745697 http://dx.doi.org/10.3390/pharmaceutics14061123 |
_version_ | 1784734837767143424 |
---|---|
author | Jahan, Sadaf Redhu, Neeru Singh Siddiqui, Arif Jamal Iqbal, Danish Khan, Johra Banawas, Saeed Alaidarous, Mohammed Alshehri, Bader Mir, Shabir Ahmad Adnan, Mohd Pant, Aditya Bhushan |
author_facet | Jahan, Sadaf Redhu, Neeru Singh Siddiqui, Arif Jamal Iqbal, Danish Khan, Johra Banawas, Saeed Alaidarous, Mohammed Alshehri, Bader Mir, Shabir Ahmad Adnan, Mohd Pant, Aditya Bhushan |
author_sort | Jahan, Sadaf |
collection | PubMed |
description | Excitotoxicity is a type of neurodegenerative disorder. It caused by excessive glutamate receptor activation, which leads to neuronal malfunction and fatality. The N-methyl-D-aspartate (NMDA) receptors are found in glutamatergic neurons, and their excessive activation is primarily responsible for excitotoxicity. They are activated by both glutamate binding and postsynaptic depolarization, facilitating Ca(2+) entry upon activation. Therefore, they are now widely acknowledged as being essential targets for excitotoxicity issues. Molecular docking and molecular dynamics (MD) simulation analyses have demonstrated that nobiletin efficiently targets the binding pocket of the NMDA receptor protein and exhibits stable dynamic behavior at the binding site. In this study, five potential neuroprotectants, nobiletin, silibinin, ononin, ginkgolide B, and epigallocatechin gallate (EGCG), were screened against the glutamate NMDA receptors in humans via computational methods. An in silico ADMET study was also performed, to predict the pharmacokinetics and toxicity profile for the expression of good drug-like behavior and a non-toxic nature. It was revealed that nobiletin fulfills the criteria for all of the drug-likeness rules (Veber, Lipinski, Ghose, Muegge, and Egan) and has neither PAINS nor structural alerts (Brenks). In conclusion, nobiletin demonstrated a possible promising neuroprotectant activities compared to other selected phytochemicals. Further, it can be evaluated in the laboratory for promising therapeutic approaches for in vitro and in vivo studies. |
format | Online Article Text |
id | pubmed-9229780 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92297802022-06-25 Nobiletin as a Neuroprotectant against NMDA Receptors: An In Silico Approach Jahan, Sadaf Redhu, Neeru Singh Siddiqui, Arif Jamal Iqbal, Danish Khan, Johra Banawas, Saeed Alaidarous, Mohammed Alshehri, Bader Mir, Shabir Ahmad Adnan, Mohd Pant, Aditya Bhushan Pharmaceutics Article Excitotoxicity is a type of neurodegenerative disorder. It caused by excessive glutamate receptor activation, which leads to neuronal malfunction and fatality. The N-methyl-D-aspartate (NMDA) receptors are found in glutamatergic neurons, and their excessive activation is primarily responsible for excitotoxicity. They are activated by both glutamate binding and postsynaptic depolarization, facilitating Ca(2+) entry upon activation. Therefore, they are now widely acknowledged as being essential targets for excitotoxicity issues. Molecular docking and molecular dynamics (MD) simulation analyses have demonstrated that nobiletin efficiently targets the binding pocket of the NMDA receptor protein and exhibits stable dynamic behavior at the binding site. In this study, five potential neuroprotectants, nobiletin, silibinin, ononin, ginkgolide B, and epigallocatechin gallate (EGCG), were screened against the glutamate NMDA receptors in humans via computational methods. An in silico ADMET study was also performed, to predict the pharmacokinetics and toxicity profile for the expression of good drug-like behavior and a non-toxic nature. It was revealed that nobiletin fulfills the criteria for all of the drug-likeness rules (Veber, Lipinski, Ghose, Muegge, and Egan) and has neither PAINS nor structural alerts (Brenks). In conclusion, nobiletin demonstrated a possible promising neuroprotectant activities compared to other selected phytochemicals. Further, it can be evaluated in the laboratory for promising therapeutic approaches for in vitro and in vivo studies. MDPI 2022-05-25 /pmc/articles/PMC9229780/ /pubmed/35745697 http://dx.doi.org/10.3390/pharmaceutics14061123 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Jahan, Sadaf Redhu, Neeru Singh Siddiqui, Arif Jamal Iqbal, Danish Khan, Johra Banawas, Saeed Alaidarous, Mohammed Alshehri, Bader Mir, Shabir Ahmad Adnan, Mohd Pant, Aditya Bhushan Nobiletin as a Neuroprotectant against NMDA Receptors: An In Silico Approach |
title | Nobiletin as a Neuroprotectant against NMDA Receptors: An In Silico Approach |
title_full | Nobiletin as a Neuroprotectant against NMDA Receptors: An In Silico Approach |
title_fullStr | Nobiletin as a Neuroprotectant against NMDA Receptors: An In Silico Approach |
title_full_unstemmed | Nobiletin as a Neuroprotectant against NMDA Receptors: An In Silico Approach |
title_short | Nobiletin as a Neuroprotectant against NMDA Receptors: An In Silico Approach |
title_sort | nobiletin as a neuroprotectant against nmda receptors: an in silico approach |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229780/ https://www.ncbi.nlm.nih.gov/pubmed/35745697 http://dx.doi.org/10.3390/pharmaceutics14061123 |
work_keys_str_mv | AT jahansadaf nobiletinasaneuroprotectantagainstnmdareceptorsaninsilicoapproach AT redhuneerusingh nobiletinasaneuroprotectantagainstnmdareceptorsaninsilicoapproach AT siddiquiarifjamal nobiletinasaneuroprotectantagainstnmdareceptorsaninsilicoapproach AT iqbaldanish nobiletinasaneuroprotectantagainstnmdareceptorsaninsilicoapproach AT khanjohra nobiletinasaneuroprotectantagainstnmdareceptorsaninsilicoapproach AT banawassaeed nobiletinasaneuroprotectantagainstnmdareceptorsaninsilicoapproach AT alaidarousmohammed nobiletinasaneuroprotectantagainstnmdareceptorsaninsilicoapproach AT alshehribader nobiletinasaneuroprotectantagainstnmdareceptorsaninsilicoapproach AT mirshabirahmad nobiletinasaneuroprotectantagainstnmdareceptorsaninsilicoapproach AT adnanmohd nobiletinasaneuroprotectantagainstnmdareceptorsaninsilicoapproach AT pantadityabhushan nobiletinasaneuroprotectantagainstnmdareceptorsaninsilicoapproach |